Esther Fernandez

Dr. Esther Fernandez


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2020 in ACS Chemical Biology
Verified
Journal Article
Closed access
CCChun-Wa Chung
Chun-Wa Chung
HDHan Dai
Han Dai
EFEsther Fernandez
Esther Fernandez
CTChristopher P. Tinworth
Christopher P. Tinworth
ICIan Churcher
Ian Churcher
ABAndrew B. Benowitz
Andrew B. Benowitz

25 June 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MJMaría Belén Jiménez-Díaz
María Belén Jiménez-Díaz
SVSara Viera-Morilla
Sara Viera-Morilla
JIJavier Ibáñez
Javier Ibáñez
TMTeresa Mulet
Teresa Mulet
NMNoemí Magán-Marchal
Noemí Magán-Marchal
IAIñigo Angulo-Barturen
Iñigo Angulo-Barturen
The emergence of resistance to available antimalarials requires the urgent development of new medicines. The recent disclosure of several thousand compounds active in vitro against the erythrocyte stage of Plasmodium falciparum has been a major breakthrough, though converting these hits into new medicines challenges current strategies. A new in vivo screening concept was evaluated as a strategy to increase the speed and efficiency of drug discovery projects in malaria. The new in vivo screening concept was developed based on human disease parameters, i.e. parasitemia in the peripheral blood of patients on hospital admission and parasite reduction ratio (PRR), which were allometrically down-scaled into P. berghei-infected mice. Mice with an initial parasitemia (P0) of 1.5% were treated orally for two consecutive days and parasitemia measured 24 h after the second dose. The assay was optimized for detection of compounds able to stop parasite replication (PRR = 1) or induce parasite clearance (PRR >1) with statistical power >99% using only two mice per experimental group. In the P. berghei in vivo screening assay, the PRR of a set of eleven antimalarials with different mechanisms of action correlated with human-equivalent data. Subsequently, 590 compounds from the Tres Cantos Antimalarial Set with activity in vitro against P. falciparum were tested at 50 mg/kg (orally) in an assay format that allowed the evaluation of hundreds of compounds per month. The rate of compounds with detectable efficacy was 11.2% and about one third of active compounds showed in vivo efficacy comparable with the most potent antimalarials used clinically. High-throughput, high-content in vivo screening could rapidly select new compounds, dramatically speeding up the discovery of new antimalarial medicines. A global multilateral collaborative project aimed at screening the significant chemical diversity within the antimalarial in vitro hits described in the literature is a feasible task.

2 September 2011 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
LRLourdes Rueda
Lourdes Rueda
ICIsabel Castellote
Isabel Castellote
JCJulia Castro-Pichel
Julia Castro-Pichel
MCMaria J. Chaparro
Maria J. Chaparro
JRJuan Carlos de la Rosa
Juan Carlos de la Rosa
EFEsther Fernandez
Esther Fernandez

10 January 2018 in ACS Infectious Diseases
Verified
Journal Article
Closed access
MCMaría Jesús Chaparro
María Jesús Chaparro
FCFélix Calderón
Félix Calderón
PCPablo Castañeda
Pablo Castañeda
EFElena Fernández-Alvaro
Elena Fernández-Alvaro
RGRaquel Gabarró
Raquel Gabarró
EFEsther Fernandez
Esther Fernandez

28 May 2021 in ACS Infectious Diseases
Verified
Journal Article
Open access
LMLydia Mata-Cantero
Lydia Mata-Cantero
SXStanley C. Xie
Stanley C. Xie
MGMercedes García
Mercedes García
JCJoanne Coyle
Joanne Coyle
RFRaquel Fernandez
Raquel Fernandez
MGMaria G. Gomez-Lorenzo
Maria G. Gomez-Lorenzo
The Ubiquitin Proteasome System is the main proteolytic pathway in eukaryotic cells, playing a role in key cellular processes. The essentiality of the Plasmodium falciparum proteasome is well validated, underlying its potential as an antimalarial target, but selective compounds are required to avoid cytotoxic effects in humans. Almost 550000 compounds were tested for the inhibition of the chymotrypsin-like activity of the P. falciparum proteasome using a Proteasome-GLO luminescence assay. Hits were confirmed in an orthogonal enzyme assay using Rho110-labeled peptides, and selectivity was assessed against the human proteasome. Four nonpeptidomimetic chemical families with some selectivity for the P. falciparum proteasome were identified and characterized in assays of proteasome trypsin and caspase activities and in parasite growth inhibition assays. Target engagement studies were performed, validating our approach. Hits identified are good starting points for the development of new antimalarial drugs and as tools to better understand proteasome function in P. falciparum.

20 August 2019
Verified
Book Chapter
Closed access
EFEsther Fernandez
Esther Fernandez
MCMaría Isabel Castellote
María Isabel Castellote
MCMaría Jesús Chaparro
María Jesús Chaparro
BDBeatriz Díaz
Beatriz Díaz
JFJorge Fernández
Jorge Fernández
FCFélix Calderón
Félix Calderón